What sector is PRTO in?

Healthcare, in the Biotechnology industry.

NYSE Arca · PRTOHealthcareBiotechnology

RCN Pareto Strategic Allocation ETF (PRTO)

$26.68−1.43%

Close Nov 12, 2026 · split-adjusted

Nov 12, 2026$26.72▼ 3.83% in range

Sep 11, 2026Low $26.42 · High $27.91Nov 12, 2026

What changed · written from our data

As of Nov 12, 2026

RCN Pareto Strategic Allocation ETF closed at $26.68 on Nov 12, down 1.43%, within 1.0% of its lowest close since Sep 28. Volume of 507 shares was 1.24× its 20-day average (close to normal).

Split-adjusted performance: -0.7% over one month.

Short interest was 107 shares at the Oct 30 settlement, down 74.8% from the prior report (1.0 days to cover).

Market cap—

Revenue · quarter$0.00—

Diluted EPS$-0.35—

P/E · TTM—

Net margin—

Dividend yieldNone

Range since Sep 2826.42 – 27.91−4.4% from high

Volume5071.24× 20-day avg

Volatility · 60d—Annualised

Short % of float—1.0 days to cover

Net cash$127.0MCash $127.0M

Next earnings—Not scheduled

Split-adjusted performance

1W +1.0%1M −0.7%3M —6M —YTD —1Y —3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size—

Industry medians: 6-month return −24.5%, revenue growth +4.6%, net margin −221.0%, P/E 19.3×.

Short interest

Details →

Shares short107−74.8% vs prior

Days to cover1.0Settled Oct 30

% of float—

Short vol. 10d30.2%of daily volume

News about RCN Pareto Strategic Allocation ETF

All news →

No recent articles focused on RCN Pareto Strategic Allocation ETF. 2 articles mention it in passing.

Quick answers

What sector is PRTO in?: Healthcare, in the Biotechnology industry.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology